Stock Scorecard
Stock Summary for LAVA Therapeutics NV (LVTX) - $1.63 as of 10/23/2025 3:56:40 AM EST
Total Score
12 out of 30
Safety Score
18 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LVTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LVTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LVTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LVTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LVTX (18 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LVTX
Financial Details for LVTX
Company Overview |
|
|---|---|
| Ticker | LVTX |
| Company Name | LAVA Therapeutics NV |
| Country | USA |
| Description | LAVA Therapeutics NV is a pioneering biotechnology company dedicated to transforming cancer treatment through its innovative gamma-delta bispecific T-cell activators (gamma-delta bsTCE). Based in Utrecht, the Netherlands, LAVA boasts a promising development pipeline that utilizes its proprietary technology to create next-generation therapies aimed at effectively targeting solid tumors and hematologic malignancies. With a strong commitment to enhancing immune responses against cancer, LAVA Therapeutics is poised to make significant contributions to oncology and improve patient outcomes in an increasingly competitive market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/12/2025 |
Stock Price History |
|
| Last Day Price | 1.63 |
| Price 4 Years Ago | 5.50 |
| Last Day Price Updated | 10/23/2025 3:56:40 AM EST |
| Last Day Volume | 2,564,476 |
| Average Daily Volume | 597,879 |
| 52-Week High | 2.06 |
| 52-Week Low | 0.85 |
| Last Price to 52 Week Low | 91.76% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.95 |
| Sector PE | 41.12 |
| 5-Year Average PE | -1.73 |
| Free Cash Flow Ratio | 1.63 |
| Industry Free Cash Flow Ratio | 14.54 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 10.78 |
| Total Cash Per Share | 1.00 |
| Book Value Per Share Most Recent Quarter | 0.76 |
| Price to Book Ratio | 2.05 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 7.80 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 26,305,300 |
| Market Capitalization | 42,877,639 |
| Institutional Ownership | 28.43% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 40.17% |
| Reported EPS 12 Trailing Months | -1.06 |
| Reported EPS Past Year | -0.44 |
| Reported EPS Prior Year | -0.89 |
| Net Income Twelve Trailing Months | -28,383,000 |
| Net Income Past Year | -25,114,000 |
| Net Income Prior Year | -41,974,000 |
| Quarterly Revenue Growth YOY | 1,314.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -522.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 26,380,000 |
| Total Cash Past Year | 35,015,000 |
| Total Cash Prior Year | 44,231,000 |
| Net Cash Position Most Recent Quarter | 26,380,000 |
| Net Cash Position Past Year | 30,375,000 |
| Long Term Debt Past Year | 4,640,000 |
| Long Term Debt Prior Year | 4,640,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.86 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 27,745,000 |
| Total Stockholder Equity Prior Year | 51,178,000 |
| Total Stockholder Equity Most Recent Quarter | 19,935,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -35,452,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.35 |
| Free Cash Flow Past Year | -19,567,000 |
| Free Cash Flow Prior Year | -39,702,999 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 1.27 |
| 20-Day Bollinger Middle Band | 1.47 |
| 20-Day Bollinger Upper Band | 1.68 |
| Beta | 0.49 |
| RSI | 35.33 |
| 50-Day SMA | 1.88 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 2.42 |
System |
|
| Modified | 10/23/2025 3:56:41 AM EST |